The Impact of Atrial Fibrillation on One-Year Mortality in Patients with Severe Lower Extremity Arterial Disease

Min-I Su1,2,3, Ying-Chih Cheng4,5, Yu-Chen Huang6,7,8

  • 1Division of Cardiology, Department of Internal Medicine, Taitung MacKay Memorial Hospital, Taitung 950, Taiwan.

Insights

Atrial fibrillation (Afib) significantly increases mortality and major adverse cardiovascular events (MACEs) in patients with severe lower extremity arterial disease (LEAD). This finding highlights the importance of considering Afib in managing severe LEAD prognosis.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Surgery
  • Clinical Outcomes Research

Background:

  • Atrial fibrillation (Afib) is known to be associated with lower extremity arterial disease (LEAD).
  • The prognostic impact of Afib on severe LEAD outcomes remains incompletely understood.
  • Severe LEAD poses significant risks for cardiovascular events and mortality.

Purpose of the Study:

  • To investigate the association between atrial fibrillation (Afib) and clinical outcomes in patients with severe lower extremity arterial disease (LEAD).
  • To determine if Afib independently predicts adverse events such as all-cause mortality and major adverse cardiovascular events (MACEs) in this patient population.

Main Methods:

  • Retrospective enrollment of consecutive severe LEAD patients undergoing percutaneous transluminal angioplasty from January 2013 to December 2018.
  • Patients were stratified based on the presence or absence of a history of Afib.
  • Follow-up for at least one year, with primary outcome of all-cause mortality and secondary outcomes including cardiac-related mortality and MACEs.

Main Results:

  • The study included 222 patients (74 ± 11 years, 54% male); 12.6% had acute limb ischemia.
  • The Afib group exhibited significantly higher rates of all-cause mortality (42.9% vs. 20.1%, p=0.014) and MACEs (32.1% vs. 14.4%, p=0.028) compared to the non-Afib group.
  • Afib was an independent predictor of all-cause mortality (adjusted HR: 2.153) and MACEs (adjusted HR: 2.338). Acute limb ischemia, Rutherford classification, and heart rate also independently predicted mortality.

Conclusions:

  • Atrial fibrillation is significantly associated with increased risks of one-year all-cause mortality and MACEs in patients with severe LEAD.
  • These findings underscore the critical prognostic role of Afib in severe arterial disease of the lower extremities.
  • Further research is warranted to explore the potential benefits of oral anticoagulants in managing Afib patients with severe LEAD.

Related Concept Videos

Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
35
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
42
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
57
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
53
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
72
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
341